Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PDZ domain containing ring finger protein 3 (PDZRN3) is a multifunctional scaffolding protein and E3 ubiquitin ligase expressed in multiple human tissues, including muscle and endothelium. PDZRN3 regulates cell differentiation, apoptosis, and proliferation by mediating the ubiquitination and proteasomal degradation of target proteins such as MUSK and β-catenin. It modulates canonical Wnt signaling and is implicated in the progression and metastasis of various cancer types, notably endometrial carcinoma, where its low expression correlates with poorer patient outcomes. PDZRN3 is under investigation as a biomarker and potential therapeutic target, with functional roles in vascular development, neurogenesis, and tissue morphogenesis documented in both experimental and clinical studies.
Drugs (potential or hypothetical) would likely act by modulating its E3 ubiquitin ligase activity, affecting ubiquitination and degradation of downstream proteins (such as MUSK or β-catenin). Modulation of Wnt/β-catenin signaling pathway: targeting PDZRN3 may attenuate cancer cell proliferation and metastasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PDZ domain containing ring finger protein 3 (PDZRN3).